trending Market Intelligence /marketintelligence/en/news-insights/trending/47TAT97wRdKEEBiiM4uWgw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Merck & Co. acquires stake in KalVista, gains access to investigational drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Merck & Co. acquires stake in KalVista, gains access to investigational drug

Merck & Co. Inc. made a $9.1 million investment in KalVista Pharmaceuticals Inc., acquiring a 9.9% stake in the company by purchasing 1,070,589 shares at $8.50 apiece.

Merck will also pay a further $37 million to help develop KalVista's investigational drug KVD001 to treat diabetic macular edema. Merck has an option to buy the treatment once it clears a phase 2 proof-of-concept trial, which will begin later this year.

Merck will also have access to any future KalVista treatments for diabetic macular edema.

If Merck exercises its option, KalVista will be eligible to receive up to a further $715 million in milestone-related payments, as well as royalties on the sale of any commercialized products.

KalVista will retain control over the products and the trial until Merck exercises its option.